Prices are updated after-hours

Professional, Scientific, and Technical Services 2022 - 06 - 15

MediXall Group, Inc.

MDXL | $0.0009 72100.0% 470

(0.0% 1d) (0.0% 1m) (50.0% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-52.7% volume)
Earnings Calendar:
Market Cap: $ 117,198
https://medixall.com/
Sec Filling | Patents | 19 employees

(US) the mission of the medixall group is to revolutionize the medical industry by improving communication; providing better technology and support services; and enabling more efficient, cost-effective healthcare for the consumer. by approaching the healthcare ecosystem as a whole, medixall creates, invests and incubates companies that embody its mission statement. the first product medixall is developing is the medixall healthcare marketplace. the medixall platform is a new generation healthcare marketplace platform to address the growing need of self-pay and high deductible consumers for greater transparency and price competition in their healthcare costs. with medixall, patient/clients find price transparency and the ability to make informed choices based on price, location and schedule for requested medical products and services. by delivering a solution that better connect consumers with high-quality healthcare providers and wellness services, medixall enable healthcare providers to en

communication

add to watch list Paper trade email alert is off

UpHealth Inc

UPH | $0.3 9.13% 0.0% 350K

Professional, Scientific, and T...

(0.0% 1d) (0.0% 1m) (-82.8% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (3.3% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 5,332,649
https://www.gigcapital2.com
Sec Filling | Patents | 2 employees

(United States) GigCapital Global is a Private-to-Public Equity investment group, sponsoring and operating Special Purpose Acquisition Companies ('SPAC', also known as Blank-Check companies). Founded in 2017 by Dr. Avi Katz, the GigCapital Group and its sponsored SPACs are led by an affiliated team of technology industry experts, deploying a unique Mentor-Investors™ methodology to partner with exceptional privately-held and U.S. and non-U.S. public technology companies led by dedicated, innovative entrepreneurs. The GigCapital Group companies offer financial, operational and executive mentoring to U.S. and global private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of the GigCapital Group with these companies continues through an organic and roll-up strategy growth post the transition to a public company.

msa acquisitions spac blank check

add to watch list Paper trade email alert is off

E-Home Household Service Holdings Ltd

EJH | $3.135 5.2% 4.94% 1.8M

Professional, Scientific, and T...

(0.0% 1d) (147.1% 1m) (522.9% 1y) (0.0% 2d) (0.0% 3d) (-3.5% 7d) (26.34% volume)
Earnings Calendar:
Market Cap: $ 430,015,513

Sec Filling | Patents | n/a employees

add to watch list Paper trade email alert is off

Finch Therapeutics Group Inc

FNCH | $2.205 -6.57% -7.03% 30K

Professional, Scientific, and T...

(0.0% 1d) (-8.0% 1m) (-79.0% 1y) (0.0% 2d) (0.0% 3d) (12.2% 7d) (-81.77% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,540,707
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

hepatitis gastrointestinal treatment injection

add to watch list Paper trade email alert is off

Doximity Inc - Class A

DOCS | News | $24.63 -0.77% -0.12% 1.7M

Professional, Scientific, and T...

(0.0% 1d) (-12.1% 1m) (-30.1% 1y) (0.0% 2d) (0.0% 3d) (-1.5% 7d) (NaN% volume)
Earnings Calendar:
Market Cap: $ 3,008,839,371
https://www.doximity.com
Sec Filling | Patents | 2021 employees

Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include over 80% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and conduct virtual patient visits. Doximity's mission is to help doctors be more productive so they can provide better health care for their patients.

urea

add to watch list Paper trade email alert is off

iCoreConnect Inc.

ICCT | $1.175 -1.26% -1.28% 29K

Professional, Scientific, and T...

(0.0% 1d) (-7.0% 1m) (941.7% 1y) (0.0% 2d) (0.0% 3d) (-3.2% 7d) (-63.12% volume)
Earnings Calendar:
Market Cap: $ 10,517,980

Sec Filling | Patents | 25 employees

icoreconnect creates software that allows anyone to share information at the highest security levels in the country, backed by highly-engaged customer support. the company provides secure communications for high-compliance industries including healthcare, finance and legal. icoreconnect’s software allows organizations and individuals to freely and easily exchange information with 2048-bit encryption, and in full compliance of current federal laws.

communication

add to watch list Paper trade email alert is off

Integrated Cannabis Solutions, Inc.

IGPK | $0.011 123.26% 23M

Professional, Scientific, and T...

(0.0% 1d) (122.2% 1m) (614.3% 1y) (0.0% 2d) (0.0% 3d) (13.6% 7d) (375.22% volume)
Earnings Calendar:
Market Cap: $ 44,019,988

Sec Filling | Patents | 1 employees

(US)

add to watch list Paper trade email alert is off

Starco Brands, Inc.

STCB 4 | $0.1397 311.77% 210K

Professional, Scientific, and T...

(0.0% 1d) (7.7% 1m) (0.0% 1y) (0.0% 2d) (7.7% 3d) (12.6% 7d) (50.97% volume)
Earnings Calendar:
Market Cap: $ 68,042,919

Sec Filling | Patents | 1 employees

starco brands (sb) is a company who’s unwavering mission is to create behavior-changing brands and products. the commitment to change the way we approach everyday activities is innate in our corporate dna. sb is an invention factory. sb's core competency is inventing products, marketing brands, building trends, pushing awareness, penetrating social media and driving traffic with cutting edge pull-through strategies. the marketing brain trust of sb is a best-in-class, globally proven team that is sought after to manage the largest brands in the world. this team is like no other, and its client experience includes apple, target, uber, volkswagen, behr paint, ralph loren and many other iconic brands. welcome to a 21st century consumer products powerhouse.

add to watch list Paper trade email alert is off

Medicine Man Technologies, Inc.

SHWZ P | $0.7 -23.21% 29K

Professional, Scientific, and T...

(0.0% 1d) (-26.0% 1m) (-35.5% 1y) (0.0% 2d) (0.0% 3d) (-10.1% 7d) (75.89% volume)
Earnings Calendar:
Market Cap: $ 32,457,779

Sec Filling | Patents | 258 employees

medicine man technologies, (symbol: mdcl), offers full service cannabis consulting and licensing of our state-of-the-art, turnkey cultivation and dispensary operating solutions. we represent and license the cultivation and dispensary ip of medicine man, a prominent tier iii colorado operator. we help clients navigate state applications, facility design, business and financial planning, as well as facilitate the adoption of operating procedures and training materials to teach your organization how to effectively operate a commercial cultivation and retail dispensary. we provide the experience and expertise to clients who have the resources necessary to enter the competitive medical and adult use cannabis marketplace, helping to mitigate the costly mistakes that many new companies will experience.

add to watch list Paper trade email alert is off

Monte Rosa Therapeutics Inc

GLUE | $5.84 -1.35% -1.37% 110K

Professional, Scientific, and T...

(0.0% 1d) (-22.1% 1m) (-4.0% 1y) (0.0% 2d) (0.0% 3d) (-11.7% 7d) (-14.89% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 292,876,000
https://www.monterosatx.com
Sec Filling | Patents | 60 employees

Monte Rosa Therapeutics is a biotechnology company discovering and developing molecular glues to degrade disease-causing proteins. The company has created a platform to rationally design small molecules that reprogram ubiquitin ligases to eliminate disease drivers previously deemed undruggable. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland.

drug discovery profitable computational machine learning

add to watch list Paper trade email alert is off

Panamera Holdings Corp

PHCI 4 | $0.9575 0% 200

Professional, Scientific, and T...

(0.0% 1d) (-16.7% 1m) (-51.7% 1y) (0.0% 2d) (0.0% 3d) (0.0% 7d) (-66.67% volume)
Earnings Calendar:
Market Cap: $ 49,225,075

Sec Filling | Patents | 2 employees

add to watch list Paper trade email alert is off

Quantum-Si Incorporated - Class A

QSI | $1.57 3.97% 3.82% 730K

Professional, Scientific, and T...

(0.0% 1d) (-20.0% 1m) (-3.8% 1y) (0.0% 2d) (-0.7% 3d) (-8.4% 7d) (NaN% volume)
Earnings Calendar: 2024-02-29
Market Cap: $ 191,276,895
https://quantum-si.com
Sec Filling | Patents | 115 employees

Quantum-Si Incorporated develops protein sequencing platform. The Company offers semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing.

drug discovery diagnostics semiconductor chip

add to watch list Paper trade email alert is off